Stocks
Acumen Pharmaceuticals, Inc.ABOS
NASDAQHealthcareBiotechnology$0.22
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing monoclonal antibody therapies for Alzheimer's disease, with its lead candidate, ACU193, targeting toxic amyloid-beta oligomers. Investors track the company for its potential to address a major unmet need in neurodegenerative disease treatment, though it has no approved products and relies on funding from partnerships and capital markets.
52W Range: $0.19-$3.60
Congressional Interest in Acumen Pharmaceuticals, Inc. (ABOS)
1 member of Congress has disclosed 4 trades in Acumen Pharmaceuticals, Inc. (ABOS), a Healthcare company. The buy/sell breakdown shows 4 purchases versus 0 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
4
Unique Politicians
1
Buys
4
Sells
0
Who in Congress Is Trading ABOS?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2021-06-16 | Mark R Warner | buy | $15K-$50K |
| 2020-11-20 | Mark R Warner | buy | $50K-$100K |
| 2019-11-15 | Mark R Warner | buy | $50K-$100K |
| 2018-10-19 | Mark R Warner | buy | $100K-$250K |